Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation

被引:39
作者
Foster, AE
Gottlieb, DJ
Sartor, M
Hertzberg, MS
Bradstock, KF [1 ]
机构
[1] Westmead Hosp, Blood & Marrow Transplant Serv, Westmead, NSW 2145, Australia
[2] Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Sydney, NSW 2006, Australia
关键词
cytotoxic T-lymphocyte; CMV reactivation; cytokine flow cytometry; allogeneic bone marrow transplantation;
D O I
10.1053/bbmt.2002.v8.pm12374455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytomegalovirus (CMV) is a common herpes virus that can cause significant morbidity and mortality in immuno-compromised individuals, particularly those undergoing allogeneic stem cell transplantation (SCT) for hematological malignancies. Recent studies have examined the kinetics of CMV-specific CD8(+) T-cell reconstitution after SCT transplantation and have found virus-specific cytotoxic T-lymphocyte regeneration to be dependent on CMV serologic status and CMV reactivation events. However, the reconstitution kinetics of CMV-specific CD4(+) T-cells under these same circumstances were not addressed. In this study, we used IIIA class I peptide tetramer for CMV pp65 and cytokine flow cytometry to follow the reconstitution of both CD4(+) and CD8(+) CMV-specific T-cells after allogeneic SCT. We found that following SCT in which both donors and recipients are CMV seropositive, virus-specific CD4(+) T-helper cells show the same reconstitution kinetics as CD8(+) cytotoxic T-cells. Following CMV reactivation, a synchronous but temporary increase in both CD4(+) and CD8(+) CMV-specific lymphocytes occurs. The pattern repeats itself after subsequent episodes of CMV reactivation. These data imply that both CD4(+) and CD8(+) lymphocytes are necessary for an efficient immune response to CMV and suggest that CD4(+) and CD8(+) CMV-specific T-cells are required for the complete restoration of CMV immunity. These findings may have important implications in the development of CMV-specific adoptive immunotherapy strategies.
引用
收藏
页码:501 / 511
页数:11
相关论文
共 47 条
[1]  
ALTMAN J, 1996, SCIENCE, V271, P94
[2]   COMPARISON OF PLASMA PCR AND BRONCHOALVEOLAR LAVAGE FLUID CULTURE FOR DETECTION OF CYTOMEGALOVIRUS-INFECTION IN ADULT BONE-MARROW TRANSPLANT RECIPIENTS [J].
ASPIN, MM ;
GALLEZHAWKINS, GM ;
GIUGNI, TD ;
TEGTMEIER, B ;
LANG, DJ ;
SCHMIDT, GM ;
FORMAN, SJ ;
ZAIA, JA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (09) :2266-2269
[3]   Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants [J].
Aubert, G ;
Hassan-Walker, AF ;
Madrigal, JA ;
Emery, VC ;
Morte, C ;
Grace, S ;
Koh, MBC ;
Potter, M ;
Prentice, HG ;
Dodi, IA ;
Travers, PJ .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (08) :955-963
[4]   Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts, unselected PBPC grafts or BM grafts [J].
Behringer, D ;
Bertz, H ;
Schmoor, C ;
Berger, C ;
Dwenger, A ;
Finke, J .
BONE MARROW TRANSPLANTATION, 1999, 24 (03) :295-302
[5]   Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study [J].
Boeckh, M ;
Gooley, TA ;
Myerson, D ;
Cunningham, T ;
Schoch, G ;
Bowden, RA .
BLOOD, 1996, 88 (10) :4063-4071
[6]  
BOLAND GJ, 1992, CLIN EXP IMMUNOL, V88, P506
[7]   Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation [J].
Broers, AEC ;
van der Holt, R ;
van Esser, JWJ ;
Gratama, JW ;
Henzen-Logmans, S ;
Kuenen-Boumeester, V ;
Löwenberg, B ;
Cornelissen, JJ .
BLOOD, 2000, 95 (07) :2240-2245
[8]   Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation [J].
Cwynarski, K ;
Ainsworth, J ;
Cobbold, M ;
Wagner, S ;
Mahendra, P ;
Apperley, J ;
Goldman, J ;
Craddock, C ;
Moss, PAH .
BLOOD, 2001, 97 (05) :1232-1240
[9]  
EINSELE H, 1995, BLOOD, V86, P2815
[10]  
ELSON LH, 1995, J IMMUNOL, V154, P4294